Earnings Routine +

Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

Bausch + Lomb Beats Q1 Estimates but Debt Overhang Persists Amid Turnaround Execution

By The Northwire Desk — AI Analysis Apr 29, 2026 · 06:58 BLCO · 21.58 BAUSCH + LOMB CORPORATION

Executive Summary

Event: Bausch + Lomb announced First-Quarter 2026 Results on April 29, 2026.
Revenue: Total revenue reached $1.244 billion, up 9% reported and 6% constant currency compared to Q1 2025.
Profitability: GAAP net loss narrowed significantly to $71 million from a loss of $212 million in the prior year period. Operating income turned positive at $33 million versus an $83 million loss previously. Adjusted EPS was $0.05 compared to a loss of $0.15.
Guidance: Full-year 2026 revenue guidance increased to $5.420 billion – $5.520 billion (from $5.375B – $5.475B). Adjusted EBITDA excluding Acquired IPR&D raised to $1.010 billion – $1.060 billion (from $1.000B – $1.050B).
Segments: Pharmaceuticals grew 14% driven by MIEBO (+33%) and XIIDRA (+30%). Vision Care up 8%, Surgical up 7%.
Balance Sheet: Cash, cash equivalents, and restricted cash totaled $279 million as of March 31, 2026.

Material Impact

Positive Execution: The company successfully narrowed its GAAP net loss by approximately $141 million quarter-over-quarter year-over-year, demonstrating improved operational leverage and cost control (Vision 27 program).
Guidance Raise: While the guidance increase is incremental ($45 million on revenue, $10 million on EBITDA), it confirms management's ability to execute the transformation plan outlined at the November 2025 Investor Day.
No Structural Change: The news does not alter the fundamental capital structure or debt burden established in December 2025 refinancing. It validates the existing thesis rather than creating a new one.
Risk Mitigation: The reduction in GAAP loss is positive, but the company remains unprofitable on a GAAP basis ($71 million loss), which limits upside for risk-averse investors until sustained profitability is achieved.

BLCO · Price

Company Overview

Overview: Bausch + Lomb is a global eye health company operating in Vision Care, Surgical, and Pharmaceuticals segments. It was spun off from Bausch Health Companies Inc. and is focused on transforming into a profitable growth entity.
Flagship Products:
- MIEBO: Prescription dry-eye therapy (Pharmaceuticals), showing strong growth (+33% in Q1).
- enVista Envy: Premium intraocular lenses (Surgical), recovering from recall issues.
- PreserVision AREDS3: New eye vitamin formulation launched early 2026 for AMD risk reduction.
Pipeline: Includes seeLYRA femtosecond laser, Elios glaucoma system, and bioactive contact lens materials targeting launches between 2026 and 2029.

More from BAUSCH + LOMB CORPORATION